ImmuCell signals operational excellence and targets $30M annual production capacity amid management transition [Seeking Alpha]
ImmuCell Corporation (ICCC)
US:NASDAQ Investor Relations:
immucell.com/investors
Company Research
Source: Seeking Alpha
Michael Brigham, Special Advisor to the CEO, described 2025 as an “exciting time at ImmuCell,” highlighting improved financial performance over the first nine months, attributing the turnaround to “increasing our production output while improving gross margins.” Brigham Quick Insights ImmuCell improved gross margins (from 26% to 43%) and moved from net loss to net income, driven by higher sales, margin gains, and expense reductions. Growth depends on capacity gains, cleared backlog, new product launches, and pending FDA approval for Re-Tain. Key challenges remain in inventory balancing and international shipment timing. Inventory is now proactively managed; backlog, though exited in June 2025, will affect sales comparisons into 2026. More Trending News
Show less
Read more
Impact Snapshot
Event Time:
ICCC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ICCC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ICCC alerts
High impacting ImmuCell Corporation news events
Weekly update
A roundup of the hottest topics
ICCC
News
- ImmuCell's Two-Product Edge in Cattle Health Fuels Growth [Yahoo! Finance]Yahoo! Finance
- ImmuCell (NASDAQ:ICCC) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- ImmuCell Corporation (ICCC) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025GlobeNewswire
- ImmuCell Announces Onboarding of New CEO and Related Management ChangesGlobeNewswire
ICCC
Sec Filings
- 12/4/25 - Form 4/A
- 12/3/25 - Form 4
- 11/28/25 - Form 4
- ICCC's page on the SEC website